Catalogs from Navinci Diagnostics
Naveni® Plex Omni Service — NextGen Spatial Interactomics run by Experts
Explore elusive proteins and functional states with Navinci’s in situ proximity ligation assay (isPLA) multiplexing system. Detect up to eight protein interactions, single proteins, or phosphorylation states simultaneously in human FFPE samples to reveal tumour–stroma crosstalk, immune cell states, and molecular networks driving disease and treatment response. With the Naveni® Plex Omni Service, your samples are analyzed by the experts behind the technology—delivering custom panels, expert-run assays, and seamless end-to-end support so you can focus on discoveries. Released November 2025.
Naveni® Plex - isPLA Multiplex Solution
Uncover complex protein interactions in the tumor microenvironment with Naveni® Plex, the groundbreaking in situ-Proximity Ligation Assay (PLA) multiplex solution designed to simultaneously detect PD1/PD-L1 interactions, PD1/PD-L2 interactions, PD1/SHP-2 interactions, CD8/MHC-I interactions and CD3 presence. Three pairs of primary antibodies conjugated to proprietary oligonucleotide arms (Navenibodies) are simultaneously incubated with your FFPE tissue sample, allowing you to map multiple protein interactions at the same time in the cancer immune interface, going beyond expression to reveal functionality. Updated January 2026.
Naveni® PD1/PD-L1 BOND RX HRP - Automated Detection of PD1/PD-L1 Interactions in situ
Immune checkpoint therapy (ICT) responses can vary among patients, underscoring the need for improved predictive biomarkers to refine patient stratification. Although PD-L1 immunohistochemistry is widely used, the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear. Now, Navinci introduces the Naveni® PD1/PD-L1 BOND RX HRP in collaboration with Leica Biosystems to evaluate the potential of PD1/PD-L1 interaction as a biomarker with a high throughput automated kit. Achieve heightened efficiency and reproducibility through an automated workflow, streamlining your research process. Released June 2024.
NaveniBright™ BOND RX HRP - Illuminating Function in Spatial Proteomics
Automated detection of protein-protein interactions and post-translational modifications in situ. The NaveniBright™ BOND RX HRP introduces a novel product line, seamlessly integrating chromogenic readout automation on the BOND RX Fully Automated Research Stainer by Leica Biosystems. This kit is meticulously crafted based on Navinci's cutting-edge Naveni® in situ proximity ligation technology, offering flexibility tailored to your unique primary antibodies and targets. With the automated workflow, you will save valuable time, reduce hands-on time and maximize your overall research productivity. Released June 2024.
Naveni™ CD8/MHC-I Atto647N - Navigate Immune Responses in situ
Dive into the secrets of immune responses with Navinci's CD8/MHC-I in situ proximity ligation assay for the detection of CD8/MHC-I interactions, providing a nuanced perspective for a detailed and accurate portrayal of the immune response. This deeper understanding becomes the cornerstone for developing targeted immunotherapies, marking a potential leap forward in precision medicine for cancer treatment. Navinci has now developed the first commercial in situ proximity ligation assay for the specific detection of CD8/MHC-I interactions. Released February 2024.
NaveniFlex™ Cell - Elevate Your Research
Since diverse sample types demand tailored treatment, our partner Navinci Diagnostics has optimized their flexible offering, aligning it even more closely with your needs. NaveniFlex™ Cell is based on the company's Naveni™ proximity ligation technology and is specifically optimized for studying protein-protein interactions and protein interplay in cell samples. It allows you to analyze even the most low-abundance protein targets with high precision and to obtain easily quantifiable data. The protocol is more than 60 minutes faster than the previous kits and it is also compatible with 96-well plates for high throughput screening. Released September 2023.
Naveni™ PD1/PD-L1 Atto647N - Illuminate PD1/PD-L1 Interactions
Unlock the potential of immune checkpoint inhibition therapy with the newest product by Navinci Diagnostics: Naveni™ PD1/PD-L1 Atto647N, the pioneering fluorescent assay for in situ detection of PD1/PD-L1 interactions. Use this assay to identify PD1/PD-L1 interactions with exceptional specificity and to visualize PD1/PD-L1 in the tumor microenvironment. Enhance the understanding of signaling pathways in the context of immune checkpoint blockade and uncover the diagnostic potential of the PD1/PD-L1 interaction. Released July 2023.
NaveniLink™ - Expanding your Options
Would you like to conjugate your own primary antibodies for using them in proximity ligation assays? The NaveniLink conjugation kit by Navinci Diagnostics allows you to do just that. You can use your primary antibodies and easily conjugate them with Navinci's proprietary oligonucleotide sequences. These conjugates can be used with the Naveni® flexible product line, which includes NaveniFlex Cell, NaveniFlex Tissue, and NaveniBright. NaveniLink offers a practical solution to enhance your research capabilities. Released April 2023.
NaveniFlex™ Tissue - An eye-opening Solution for Tissue Samples
Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology developed by Navinci Diagnostics for NaveniFlex™ Tissue kits is tailor-made to overcome common background challenges in tissue samples. The kits are optimized to deliver highly reproducible and accurate results even for the least abundant protein interactions. NaveniFlex™ Tissue is an eye-opening solution for your tissue samples. Released January 2023.
Naveni™ TriFlex Cell - Discover the Secret Life of Proteins
Ever wished there was a way to take a snapshot of two proteins as they interact or remain unbound? The door to studying protein interplay and functional states while retaining the structural integrity of the cell is now open! Find out about protein complex formation and disassembly in response to different stimuli in situ with the help of Navinci's latest innovation. Naveni™ TriFlex Cell is a revolutionary proximity-based technology that can concurrently visualize two proteins in a free and complex state in any cell compartment. It aids you in elucidating the spatiotemporal communication between proteins in their native environment. With Naveni™ TriFlex Cell, you can detect the relative amounts of total protein A, total protein B, and the interaction AB between the two proteins. Understanding the relationship between your favorite proteins has never been easier! Released January 2023.
Naveni™ PD1/PD-L1 - Detect PD1/PD-L1 Interactions in situ
Despite the recent success of immune checkpoint inhibitors, many patients do not benefit from these therapies, and predictive biomarkers improving patient stratification are needed. PD-L1 IHC is commonly used as a biomarker, but the correlation between PD-L1 expression levels and PD1/PD-L1 interaction is not always linear. Navinci Diagnostics has now developed the first commercial Proximity Ligation Assay for the specific detection of PD1/PD-L1 interactions in situ. Released September 2022.
NaveniBright™ - BRINGING PRECISION TO SPATIAL PROTEOMICS
In situ detection of protein-protein interactions and post-translational modifications: The NaveniBright™ is a new Naveni product line with chromogenic readout. The in situ kits are based on the proprietary Naveni™ Proximity Ligation Technology. The assay significantly enhances the chromogenic signal, providing a stronger and more accurate staining of cell or tissue samples. Released May 2022.